Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 3/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.33 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405641 | 0.92 | FFAR4 (0.32) | CNR1ESR1ESR2PIM1FFAR4 | |
| SCHEMBL2408111 | 0.85 | PRKD1 (0.37) | CNR1PIM2PIM1FFAR4 | |
| SCHEMBL2406060 | 0.85 | DKK1 (0.42) | CNR1ESR1ESR2PIM2PIM1 | |
| SCHEMBL2407113 | 0.84 | SMN1; SMN2 (0.44) | CNR1WDR5PIM2PIM1FFAR4 | |
| SCHEMBL2405635 | 0.84 | PIM2 (0.36) | CNR1ESR1ESR2PIM2PIM1 | |
| SCHEMBL2406718 | 0.84 | KMO (0.38) | CNR1FFAR4 | |
| SCHEMBL2405902 | 0.84 | FFAR4 (0.41) | CNR1FFAR4 | |
| SCHEMBL2407614 | 0.83 | FFAR4 (0.42) | CNR1WDR5FFAR4 | |
| SCHEMBL2404770 | 0.83 | USP2 (0.36) | CNR1ESR1ESR2PIM2PIM1 | |
| SCHEMBL2410765 | 0.83 | CNR1 (0.46) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | CNR1 39/4885ESR1 3638/4885ESR2 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.